Skip to content

Study · Animal study (in vivo) · mouse · 2022

6 results

Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice.

Nickel K, Zhu L, Mangalindan R, Snyder JM, Tucker M, Whitson J, Sweetwyne M, Valencia AP, Klug J, Jiang Z, Marcinek DJ, Rabinovitch P, Ladiges W

Aging pathobiology and therapeutics30 Sept 2022Cited by 10 (Europe PMC)

PMID36250163 (opens in a new tab)PMCIDPMC9562127 (opens in a new tab)DOI10.31491/apt.2022.09.089 (opens in a new tab)PepBankPUB-36250163
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In aged male C57BL/6 mice, long-term elamipretide improved physical performance versus saline.

    In plain wordsIn aged male mice, long-term elamipretide improved physical performance compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePhysical performance in males
    Study

    mousen: not reported in source

    C57BL/6 mice, 18 months old at start, regular chow or high-fat diet
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    3 mg/kg, 5 days per week · subcutaneous · 10 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Elam improved the physical performance of males but not females, while in females Elam improved cognitive performance and enhanced the maintenance of body weight and fat mass.
    2 context sentences
    Summary · context
    The present study was designed to examine the phenotypic effects of long-term Elam treatment on aging in C57BL/6 mice starting at 18 months of age.
    Summary · context
    Mice were fed regular chow (RC diet) or a diet high in fat and sugar (HF diet) and treated with 3 mg/kg of Elam or saline subcutaneously 5 days per week for 10 months.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In aged female C57BL/6 mice, long-term elamipretide did not improve physical performance.

    In plain wordsIn aged female mice, long-term elamipretide did not improve physical performance.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changePhysical performance in females
    Study

    mousen: not reported in source

    C57BL/6 mice, 18 months old at start, regular chow or high-fat diet
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    3 mg/kg, 5 days per week · subcutaneous · 10 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Elam improved the physical performance of males but not females
    2 context sentences
    Summary · context
    The present study was designed to examine the phenotypic effects of long-term Elam treatment on aging in C57BL/6 mice starting at 18 months of age.
    Summary · context
    Mice were fed regular chow (RC diet) or a diet high in fat and sugar (HF diet) and treated with 3 mg/kg of Elam or saline subcutaneously 5 days per week for 10 months.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In aged female C57BL/6 mice, long-term elamipretide improved cognitive performance.

    In plain wordsIn aged female mice, long-term elamipretide improved cognitive performance.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCognitive performance in females
    Study

    mousen: not reported in source

    C57BL/6 mice, 18 months old at start, regular chow or high-fat diet
    Comparator
    Saline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    3 mg/kg, 5 days per week · subcutaneous · 10 monthsAs given in this study (mouse).

    Source sentences

    Summary
    while in females Elam improved cognitive performance and enhanced the maintenance of body weight and fat mass.
    2 context sentences
    Summary · context
    The present study was designed to examine the phenotypic effects of long-term Elam treatment on aging in C57BL/6 mice starting at 18 months of age.
    Summary · context
    Mice were fed regular chow (RC diet) or a diet high in fat and sugar (HF diet) and treated with 3 mg/kg of Elam or saline subcutaneously 5 days per week for 10 months.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In aged female C57BL/6 mice, long-term elamipretide enhanced the maintenance of body weight.

    In plain wordsIn aged female mice, long-term elamipretide helped keep body weight.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedMaintenance of body weight in females
    Study

    mousen: not reported in source

    C57BL/6 mice, 18 months old at start, regular chow or high-fat diet
    Comparator
    Saline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg/kg, 5 days per week · subcutaneous · 10 monthsAs given in this study (mouse).

    Source sentences

    Summary
    while in females Elam improved cognitive performance and enhanced the maintenance of body weight and fat mass.
    2 context sentences
    Summary · context
    The present study was designed to examine the phenotypic effects of long-term Elam treatment on aging in C57BL/6 mice starting at 18 months of age.
    Summary · context
    Mice were fed regular chow (RC diet) or a diet high in fat and sugar (HF diet) and treated with 3 mg/kg of Elam or saline subcutaneously 5 days per week for 10 months.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In aged female C57BL/6 mice, long-term elamipretide enhanced the maintenance of fat mass.

    In plain wordsIn aged female mice, long-term elamipretide helped keep fat mass.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedMaintenance of fat mass in females
    Study

    mousen: not reported in source

    C57BL/6 mice, 18 months old at start, regular chow or high-fat diet
    Comparator
    Saline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg/kg, 5 days per week · subcutaneous · 10 monthsAs given in this study (mouse).

    Source sentences

    Summary
    while in females Elam improved cognitive performance and enhanced the maintenance of body weight and fat mass.
    2 context sentences
    Summary · context
    The present study was designed to examine the phenotypic effects of long-term Elam treatment on aging in C57BL/6 mice starting at 18 months of age.
    Summary · context
    Mice were fed regular chow (RC diet) or a diet high in fat and sugar (HF diet) and treated with 3 mg/kg of Elam or saline subcutaneously 5 days per week for 10 months.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In aged male and female C57BL/6 mice, long-term elamipretide improved diastolic function, more in males.

    In plain wordsIn aged mice, long-term elamipretide improved heart relaxation in both sexes, more in males.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseDiastolic function
    Study

    mousen: not reported in source

    C57BL/6 mice, 18 months old at start, regular chow or high-fat diet
    Comparator
    Saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    3 mg/kg, 5 days per week · subcutaneous · 10 monthsAs given in this study (mouse).

    Source sentences

    Summary
    It also improved diastolic function in both males and females, but to a greater extent in males.
    2 context sentences
    Summary · context
    The present study was designed to examine the phenotypic effects of long-term Elam treatment on aging in C57BL/6 mice starting at 18 months of age.
    Summary · context
    Mice were fed regular chow (RC diet) or a diet high in fat and sugar (HF diet) and treated with 3 mg/kg of Elam or saline subcutaneously 5 days per week for 10 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.